New Toujeo SoloStar pen provides important dosing information

Sanofi has received FDA approval of Toujeo® (insulin glargine [rDNA origin] injection), a next-generation Lantus®. Like Lantus, Toujeo is a once-daily, long-acting basal insulin that is designed to improve glycemic control in patients with type 1 or type 2 diabetes; however, Toujeo offers a stronger version.

  • penv2Toujeo comes in a 1.5 mL disposable, prefilled Toujeo® SoloStar® pen that contains 450 units – 50 percent more than the 300-unit Lantus® SoloStar® pen.

  • Toujeo contains three times as much insulin in 1 milliliter (mL) of liquid (300 units/mL) as standard insulin (100 units/mL). As a result, the Toujeo SoloStar pen requires one-third the injection volume to deliver the same number of insulin units as the Lantus SoloStar pen.

Please note that you must use the Toujeo SoloStar disposable prefilled pen provided by the manufacturer to administer this medication. The dose counter on this pen shows the number of units of Toujeo to inject. This pen was specifically designed for Toujeo, so no dose conversion is needed.

For more information
If you have any questions about Toujeo or using the Toujeo SoloStar pen, please contact our pharmacy staff at (800) 462-5760.

Print